Amneal Pharmaceuticals is now shipping Arsenic Trioxide Injection, approved as an Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA).

Arsenic Trioxide is a generic equivalent for Trisenox® and indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

Important Safety Information includes a boxed warning on differentiation syndrome, cardiac conduction abnormalities and encephalopathy including Wernicke’s. 

Differentiation Syndrome: Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide have experienced differentiation syndrome, which may be life-threatening or fatal. Signs and symptoms may include unexplained fever, dyspnea, hypoxia, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, weight gain, peripheral edema, hypotension, and renal insufficiency, hepatopathy, and multi-organ dysfunction, in the presence or absence of leukocytosis. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. Temporarily withhold arsenic trioxide.

Cardiac Conduction Abnormalities: Arsenic trioxide can cause QTc interval prolongation, complete atrioventricular block and torsade de pointes, which can be fatal. Before administering arsenic trioxide, assess the QTc interval, correct electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide to patients with a ventricular arrhythmia or prolonged QTc interval. Withhold arsenic trioxide until resolution and resume at reduced dose for QTc prolongation.

Encephalopathy: Serious encephalopathy, including Wernicke’s, has occurred with arsenic trioxide. Wernicke’s is a neurologic emergency. Consider testing thiamine levels in patients at risk for thiamine deficiency. Administer parenteral thiamine in patients with or at risk for thiamine deficiency. Monitor patients for neurological symptoms and nutritional status while receiving arsenic trioxide. 

If Wernicke’s encephalopathy is suspected, immediately interrupt arsenic trioxide and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize. 

Click here for full prescribing information including boxed warning.

Amneal’s AP-rated Arsenic Trioxide Injection is packaged in ten 10 mg/10 mL (1 mg/mL) and 12 mg/6 mL (2 mg/mL) single-dose vials.

According to IQVIA®, U.S. annual Arsenic Trioxide Injection sales for the 12 months ended July 2021 were approximately $26.3 million.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated pharmaceutical company focused on the development, manufacturing, and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

The Company also owns 65% of AvKARE. AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. For more information, visit 

Articles

Amneal Launches Arsenic Trioxide Injection – Generic for Trisenox

With the heightened need for medical care and prescription drugs, the demand for immunization services at an all-time-high, and a noticeable scarcity of primary care physicians, the community pharmacists of rural Kentucky have emerged as the most accessible health care providers in a period defined by COVID-19.

While the critical role of the pharmacist might have been spotlighted this year, it didn’t take a global pandemic for University of Kentucky College of Pharmacy leaders to start believing in the future of community pharmacy. They acknowledge that community pharmacists are impeccably positioned to bridge the gaps in care that exist in rural Kentucky’s medical deserts.

In alignment with the college’s long-standing commitment to practice innovation, the University of Kentucky College of Pharmacy has invested in the Flip the Pharmacy initiative through sponsorship of Team Kentucky. Flip the Pharmacy is a 5-year pharmacy transformation program aiming to re-work community-based pharmacy practice beyond filling prescriptions and toward an ongoing focus on a patient's health.

The college’s practice advancement efforts are spearheaded by the Center for Advancement of Pharmacy Practice (CAPP), which was established by the University of Kentucky College of Pharmacy to transform pharmacy practice within Kentucky and the nation. Through research, education, engagement and scholarship, CAPP facilitates the creation and translation of novel care delivery models within pharmacy practice that improve medication use and health outcomes.

At the forefront of these efforts is Brooke Hudspeth, PharmD, chief practice officer (CPO) and associate dean of pharmacy practice. She is the program administrator for Team Kentucky of Flip the Pharmacy.

Hudspeth shares that the University of Kentucky College of Pharmacy’s investment in Flip the Pharmacy will provide direct coaching to 12 participating pharmacies throughout Kentucky.

Through a collaboration with Sullivan University College of Pharmacy and Health Sciences, coaches from both colleges convene monthly to discuss their respective pharmacies’ progress.

Using monthly change packages, Flip the Pharmacy coaches work with local pharmacy teams to implement the 6 key transformation domains with an emphasis on continuing patient care planning with documentation in various eCare Plan platforms.

Hudspeth elaborates, “In support of Flip the Pharmacy, we have implemented virtual continuing education programming focused on diabetes melitus. These sessions provide pharmacists across the state with tangible resources that will enable them to provide enhanced care and improve health outcomes for these patients.”

Furthermore, Hudspeth oversees all community pharmacy efforts for the college and actively strives to engage students in practice transformation efforts. As a member of the ACT (Academia-CPESN Transformation) Pharmacy Collaborative, the University of Kentucky College of Pharmacy is focused on developing a curriculum framework that incorporates elements of the advanced community pharmacy practice model.

The University of Kentucky College of Pharmacy has pioneered several programs aimed to expose students to pharmacy practice transformation in its Doctor of Pharmacy program. Their Patient-Centered Care Experience Laboratory utilizes a layered-learning model that integrates Pharmacist eCare Plan documentation, a key component of the Flip the Pharmacy program.

Additionally, their Longitudinal Experiential Education in Pharmacy program immerses students in pharmacy practice through hands-on experience in various pharmacy settings.

According to Hudspeth, learning doesn’t stop after pharmacy school.

“Practice advancement is lifelong learning,” Hudspeth points out. “The process is always evolving as we launch new projects, develop upcoming pharmacy leaders, and forge lasting partnerships with other organizations.”

By cultivating a new generation of community pharmacists, the University of Kentucky College of Pharmacy demonstrates its commitment to increasing patient access to pharmacist-provided care beyond the pandemic. Equipped with the skills and experiences rooted in Flip them Pharmacy, students will be prepared to carry pharmacy forward and reach the rural communities that need pharmacists most.

The University of Kentucky College of Pharmacy is located in Lexington, Kentucky and was ranked by U.S. News & World Report as one of the nation's top ten pharmacy programs in 2020.

The Flip the Pharmacy program hopes to directly support 1,000 pharmacies and impact thousands more. To date, over 800 pharmacies are receiving direct coaching and implementation support. Learn more at 

By sponsoring Team Kentucky of Flip the Pharmacy, the Center for Advancement of Pharmacy Practice at the University of Kentucky College of Pharmacy is leading the way for academic institutions engaged in transforming community-based pharmacy practice.

University of Kentucky College of Pharmacy Commits to Community Pharmacy Practice Transformation

While many small businesses crumbled during the COVID-19 pandemic, the team at Cave’s Drug leveraged the opportunity to provide patient care in remarkable new ways.

For over 50 years, the independent pharmacy survived on simply filling prescriptions and offered limited clinical services. However, Ashley Bates, PharmD, faced the reality that her pharmacy’s longtime product-based reimbursement model was neither sustainable, nor reflective of the needs of her community. Now, Ashley is the Flip the Pharmacy

Champion for Cave’s Drug and leads its practice transformation effort. She claims that her team has emerged from the pandemic stronger than ever. Located in Kingsport, Tennessee, Cave’s Drug has served the communities of Fall Branch, Colonial Heights, and Rock Springs for since 1969. Cave’s Drug participates in CPESN®Tennessee and CPESN USA.

Ashley is the pharmacy manager at Cave’s Drug, which started the Flip the Pharmacy program in October 2020, along with 340 other pharmacies across the country.

Flip the Pharmacy is a 5-year pharmacy transformation program aiming to re-work community-based pharmacy practice beyond filling prescriptions and toward an ongoing focus on a patient's health. Ashley shares that Cave’s Drug’s participation in Flip the Pharmacy has enabled her pharmacy to significantly expand their menu of enhanced clinical services.

Using monthly change packages, Flip the Pharmacy coaches work with local pharmacy teams to implement the six key transformation domains with an emphasis on continuing patient care planning with documentation in various eCare Plan platforms.

Ashley explains, “Before Flip the Pharmacy, the only clinical services we offered were seasonal flu shots. With changes to our workflow, we’ve been able to engage pharmacy technicians in vaccine administration and screening. Now, we average about 30 vaccines per day.” 

The team at Cave’s Drug has played a vital role in protecting their community from COVID-19, administering hundreds of vaccines in the pharmacy parking lot and even traveling to homebound patients.

In addition to vaccines, Cave’s Drug has begun offering many other enhanced clinical services since joining the Flip the Pharmacy movement. For example, the pharmacy has enrolled over 150 patients in their medication synchronization and adherence packaging programs.

“We had a regular patient who would call the pharmacy two or three times per week with questions. She was confused about which medications she should be taking and when,” Ashley recalls. “A staff member drove to her home to pick up the medications and returned them in adherence packaging.” Now the patient is enrolled in medication synchronization and consistently takes her medications as prescribed.

Ashley gives much credit to their Flip the Pharmacy coach, Amber Suthers, CPhT, MSAH, stating, “she is an invaluable resource who is always responsive, with answers just a phone call or email away.” Flip the Pharmacy coaches are funded by the Community Pharmacy Foundation and national and local team sponsors. Cave’s Drug is a member of Team Greater Appalachian Transformation Effort, which is funded in part by a team sponsorship donation from Corley’s Pharmacy, Inc.

The team at Cave’s Drug is just getting started. In the future, they want to continue expanding their services to include point-of-care testing and disease state education.

When asked about her pharmacy’s next steps, Ashley answers confidently, “The traditional retail pharmacy model is 10% of pharmacists’ potential. Flip the Pharmacy gives pharmacists the opportunity to do more.”

The Flip the Pharmacy program hopes to directly support 1,000 pharmacies, just like Cave’s Drug with coaches like Amber, and impact thousands more. To date, over 800 pharmacies are receiving direct coaching and implementation support. Learn more at 

Using monthly change packages, Flip the Pharmacy coaches work with local pharmacy teams to implement the six key transformation domains.


Emerging From COVID-19 With Resilience

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg, a therapeutic equivalent generic version of Librax® (chlordiazepoxide hydrochloride and clidinium bromide) approved by the U.S. Food and Drug Administration (USFDA).

The Librax® brand and generic market had U.S. sales of approximately $105.9 million MAT for the most recent twelve months ending in July 2021 according to IQVIA Health*.

Dr. Reddy’s Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100.

Please click here for full prescribing information including boxed warning: https://www.drreddys.com/pil/Chlordiazepoxide-Hyd-Clidinium-Bromid-Cap_Outsert-v_5-PI.pdf

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS and PRECAUTIONS, Drug Interactions).

The use of benzodiazepines, including chlodiazepoxide hydrochloride, a component of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS).

The continued use of benzodiazepines, including Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules or reduce the dosage (see WARNINGS and DOSAGE AND ADMINISTRATION).

: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.

Dr. Reddy's Laboratories Announces Launch of Chlordiazepoxide Hydrochloride, Clidinium Bromide Capsules, USP in the US Market

When the Centers for Medicare & Medicaid Services (CMS) added a new Condition of Participation (CoP) requiring hospitals to send electronic patient event notifications to alert primary care providers and post-acute care providers of a patient’s admission, discharge, or transfer to another healthcare facility, Cancer Treatment Centers of America® (CTCA) took it several steps further. They built new technology that not only complied with the requirement by the deadline of May 1, 2021, but also is poised to expand its capabilities to engage with referring providers.

In partnership with MedAllies, a leading national interoperable network and Health Information Service Provider (HISP), CTCA leveraged its own systems to connect with the MedAllies HISP platform and created an innovative proprietary technological solution to meet the CoP notification requirements. Utilizing its Patient Notification Hub, which streams real-time patient events into a centralized location, CTCA partnered with MedAllies to build a solution that subscribes to any event included in CoP notification requirements. Through the Patient Notification Hub, the solution seamlessly sends event notifications securely in real-time to patients’ known providers. Leveraging cloud-native serverless infrastructure, this event sourcing solution can easily be enhanced to meet changing needs within the healthcare industry and can be adapted when legislative changes require adding or removing event types. 

“Through technological innovation that keeps referring providers informed at an event level, we enhance the personalized patient-centered approach to care that CTCA is committed to delivering,” said CTCA Chief Information Officer, 

Building upon this solution, CTCA is aiming to integrate the Patient Notification Hub with its recently released Provider Portal. Utilizing the Provider Portal, referring providers within the CTCA network can easily refer patients and receive updates on all clinically relevant information and patient events. At its core, the Provider Portal creates efficiency in the referral process and enhances communication and collaboration between patients’ CTCA care teams and referring providers.

“MedAllies is honored to partner with a world-class organization like CTCA by providing a component of their recent innovation to address this CoP mandate and set the stage for them to deliver additional capabilities to their care teams,” said MedAllies Chief Commercial Officer, Tom Visotsky.

About Cancer Treatment Centers of America


Cancer Treatment Centers of America® (CTCA) is a national oncology network of 

offering an integrated approach that combines surgery, radiation, chemotherapy, immunotherapy and advancements in precision medicine with supportive therapies to manage side effects and enhance quality of life during treatment and into survivorship. CTCA® publishes 

 bi-annually including patient experience, length of life, quality of life, patient safety and quality of care. CTCA also offers qualified patients a range of clinical trials that may reveal new treatment options supported by scientific and investigational research. CTCA patient satisfaction scores consistently rank among the highest for all cancer care providers in the country. Visit 

MedAllies securely delivers vital health information to impact care by operating a nationwide interoperable network supporting all healthcare constituents. We are focused on optimizing the adoption and usage of healthcare interoperability for the people, systems and services connected to our MedAllies network, eliminating information care gaps and fostering a truly interoperable and connected future. We serve more than 700 hospitals, 100,000 providers and dozens of vendor partners bringing together millions for a more fluid healthcare experience. Learn more at 

CTCA leverages new CMS Conditions of Participation notification requirements as opportunity for innovation.

Cancer Treatment Centers of America Partners with MedAllies to Innovate on Best-in-Class Patient Notifications for CMS and Provider Network

 and supported by the CDC comparing manual and electronic blood pressure monitors demonstrated that medical professionals could replace the mercury sphygmomanometer traditionally used in physician offices with an automated monitor such as the OMRON HEM-907XL and maintain consistent medical-grade accuracy. 

Researchers found the OMRON HEM-907XL matched the accuracy of mercury sphygmomanometers and concluded that making the switch to the automated blood pressure monitor could reduce and eliminate the presence of mercury in blood pressure monitors, and achieve environmental benefits and cost effectiveness for medical practices.

“OMRON blood pressure monitors are reviewed by the FDA, cleared as medical devices, and rank as the number one brand among physicians and pharmacists. This new study is a testament to the accuracy and reliability of our medical devices,” said Jim Li, executive director, Global Medical Affairs for OMRON Healthcare. “This study highlights the opportunity for medical professionals and benefits the environment by replacing the mercury sphygmomanometer.”

The test group was comprised of 4,477 eligible participants over a one-year period with ages ranging from 18 through 60 and over. Within the test group, blood pressure was measured using two protocols – the auscultation protocol (AP) administered by a physician using a mercury sphygmomanometer and the oscillometric protocol (OP) administered by a health technician using an OMRON HEM-907XL device – in a randomly assigned order. Between-protocol, mean systolic BP and diastolic BP measurements were compared. Then, the prevalence of stage 1 high blood pressure was determined, and protocols were evaluated.

Results showed that although mean systolic BP and diastolic BP obtained by AP and OP differed, the prevalence of stage 1 high blood pressure did not differ, suggesting that a change in protocol may not affect blood pressure prevalence estimates.

This research adds to a body of established science on OMRON’s HEM-907XL, which is clinically validated for accuracy and designed for use in a professional setting including a physician’s office, hospital, or other point of care environment.For more information on OMRON’s HEM-907XL or Professional Intellisense® Blood Pressure Monitor, visit 

OMRON Healthcare, Inc., is the world’s leading manufacturer and distributor of personal heart health products, and an innovator in technologies supporting respiratory and pain management care. With more than 40 years of medical device category leadership, OMRON is passionate about empowering people to take charge of their health at home through precise technology. Its market-leading products include a full-range of home blood pressure monitors, nebulizers and TENS devices. The company’s mission is Going for Zero, the elimination of heart attacks and strokes. For more information, visit 

Published research supported by the CDC highlights environmental and cost-savings benefits of replacing mercury sphygmomanometers with electronic blood pressure monitors.

New Study Shows Consistent Medical-Grade Accuracy and Environmental Benefits to Replacing Mercury Sphygmomanometers with OMRON HEM-907XL

In 2012, the Community Pharmacy Foundation (CPF) and the National Council for Prescription Drug Programs (NCPDP) began an organizational collaboration with the goal of increasing representation of independent community pharmacists within NCPDP membership and forums.

The CPF is a non-profit organization dedicated to advancing community pharmacy practice and patient care delivery. NCPDP is a not-for-profit, ANSI-accredited Standards Development Organization (SDO) that relies on its collaborative, consensus-building process to develop national standards for real-time, electronic exchange of health care information, and creation of best practices for patient safety.

Historically, NCPDP membership among independent community pharmacist-owners was underrepresented. Reasons for the lower involvement may be explained in part by independent pharmacist owners’ day-to-day pharmacy operations obligations making their time and resources scarce compared to other community pharmacists.

 Also, pharmacy owners may have difficulty affording the extra expense of covering their shifts within the pharmacy to actively participate in NCPDP.

Further, although NCPDP has a very large impact on the daily workflow of pharmacies, many community pharmacists are unaware of its existence and the benefits of having direct participation within the organization. Therefore, to help address this gap, the CPF approved grant funding to facilitate the active participation of independent community pharmacist stakeholders.

A core group of community pharmacists identified by the National Community Pharmacy Association (NCPA) began participating as NCPDP members in 2013.

 The new members were invited to serve on committees and work groups where the standards development process occurs.

Work Groups include areas such as telecommunication, product identification, government programs, professional pharmacy services, ePrescribing and related transactions, and long-term post-acute care.

 Participants have diverse backgrounds and represent various geographic areas across the United States.

Christian Tadrus, PharmD, RPh, is an independent community pharmacist-owner selected to participate as part of the CPF/NCPDP collaboration. Tadrus has had the opportunity to participate in multiple areas of NCPDP since 2013.

He has been a Consensus Group member, Educational Programs Advisory Group member, Bylaws Committee member, and NCPDP SCRIPT Standard Version 10.6 Certification Program Reviewer. He also served on the board of trustees (BOT) and served as the vice chair of the Strategic Planning Committee. The BOT members establish strategic direction, provide fiduciary oversight, and serve as ambassadors of NCPDP.

As part of his role, Tadrus participated in NCPDP’s development of NCPDP’s Standards-based Facilitator Model. The Facilitator Model leverages existing bidirectional, interoperable industry standards that are widely used nationwide by prescribers and dispensers today.

The Facilitator Model supports state efforts to more effectively address public health crises, such as the opioid epidemic and COVID-19 through real-time and bi-directional communication within provider workflow. Tadrus sees one of the most significant developments for pharmacy has been in the creation of a pharmacy-centric, interoperable tool for patient care planning called the Pharmacist eCare Plan (

 The Pharmacist eCare Plan helps track chronic care activities and/or interventional activities in a standardized way to help better contribute to the patient’s care plan.

Furthermore, the eCare plan provides a way outside an integrated healthcare system for the pharmacy team to receive information and interact with the rest of the care team. It also supports value-based care models and the billing structure needed for the pharmacy to be paid for its services. CPF was a major supporter of this strategic initiative and is also one of the primary adopters of this technology in the real-world setting.

Tadrus states that this interoperability technology has the potential to change the future of pharmacy and is grateful for the collaboration between NCPDP and CPF to help facilitate some of these programs and give independent community pharmacists a greater voice.

Community Pharmacy Foundation. About Us. CPF. Accessed June 27, 2021. 

https://communitypharmacyfoundation.org/about/default.asp

National Council for Prescription Drug Programs. Who We Are. NCPDP. June 27, 2021. 

Community Pharmacy Foundation. Grant Application #71158. CPF. Accessed June 27, 2021. 

https://communitypharmacyfoundation.org/resources/grant_docs/CPFGrantDoc_55859.pdf

Spiro S. Pharmacist e Care Plan Initiative. PHIT Collaborative. Accessed June 27, 2021. 

Interoperability technology has the potential to change the future of pharmacy.

The Impact of Independent Community Pharmacists on NCPDP Standards 

Camber's new headquarters and distribution facility in Piscataway, New Jersey is now operational. Many of the Camber team members have moved into the new building, products are being staged for shipping and distribution from the new center will start this fall.

Camber now has 2 locations in Piscataway, along with other distribution centers in New York and Tennessee – bringing Camber’s total footprint to 350,000 square feet in the United States

What does this mean for customers and patients?

“It was obvious that Camber needed additional distribution capabilities to continue the uninterrupted supply of generic products to our customers,” Kon Ostaficiuk, President of Camber Pharmaceuticals, said during a recent interview. “With the new headquarters at 800 (Centennial Avenue), and our other US locations, we continue to maintain at least a 3-month safety supply of Camber products.”

In late 2019, the company acquired the new property and started outfitting the warehouse and office spaces in early 2020.

The idea was to create more office space and allow the team to grow with the needs of our customers

," noted Ostaficiuk.Camber now employs over 100 team members in the NJ locations - with an additional 13 open positions needed to support further growth demands. Hetero Labs, Camber’s parent company has over 23,000 team members located in 126 countries.

We are focused on the future of generics. Investing in additional space, demonstrates our commitment to patients and our customers

With so many new launches expected through 2021 and 2022, the company is more than prepared to ensure a steady supply of products – always available when needed.

Camber will start conducting a limited number of private facility tours this fall. Contact your representative to schedule a tour of our new headquarters today!

Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products. Its parent company, Hetero Drugs of Hyderabad India, is one of the world’s leading API and finished dosage manufacturers. Camber’s commitment to the consumer is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.

Camber Pharmaceuticals Opens New Headquarters

®, the leading media resource for pharmacists, and Parata Systems, the leading provider of pharmacy automation, 30 pharmacy professionals have been named finalists of the 

 awards. Ten category winners will be announced at the Next-Generation Pharmacist® of the Year gala, which will be held at 6pm on October 8, 2021, at Founder's Hall in Charlotte, N.C.

"Now in its 12th year, the Next-Generation Pharmacist® awards program is an opportunity to recognize and honor the outstanding finalists that are driving innovation in the pharmacy industry," said Mike Hennessy Jr., president and CEO of MJH Life Sciences™, parent company of 

®. "In collaboration with Parata, we look forward to celebrating all of the finalists and winners later this fall."


This peer-nominated awards program is designed to honor exceptional pharmacists, student pharmacists, technicians, and industry advocates across 10 specialized categories. A panel of renowned judges selected three finalists in each of the categories that are representative of the many roles within the pharmacy industry. The finalist's pharmacy practice settings range from large chain retailers to independent pharmacies, specialty pharmacies, military bases, health clinics, and educational institutions.

The 2021 Next-Generation Pharmacist® finalists are:

, PharmD, MPH, Central Florida Pharmacy Council

, PharmD, BCACP, BGCP, CPP, Wingate University Levine College of Health Sciences

, PharmD, Pevely Rx, Inc. DBA Medicine Shoppe

, PharmD, South College School of Pharmacy 

, PharmD, BCPS, BC-ADM, CTTS, WVU Medicine, Tobacco-Free Me

, PharmD, Licensed Immunizing Pharmacist, Touro College of Pharmacy, Queens College and CUNY Research Foundation, CVS Pharmacy

, PharmD, FCCP, FAPhA, FFIP, University of Health Sciences and Pharmacy in St. Louis

, BS, PharmD, MBA, FAPhA, Mayo Clinic Florida

, PharmD, FCCP, BCPS, BCACP, University of Health Sciences and Pharmacy

, PharmD, CPESN USA / Duvall Family Drugs

 Pharm.D., United States Air Force, Joint Base Elmendorf Richardson Element Chief, Inpatient Pharmacy

, PharmD, MS, BCPS, UNC Health; UNC Eshelman School of Pharmacy

, PharmD, Walgreens Specialty Pharmacy at Children's National Medical Center

"Pharmacies are performing exponentially more services than ever before, showcasing an overwhelming display of innovation, entrepreneurship, and leadership across what has become an immensely interdisciplinary practice," said Rob Kill, Parata CEO. "We are honored to celebrate our nation's top pharmacists, both current and future - and congratulate all of those nominated in 2021."

Winners will be selected from each of the categories and one finalist will be named the 2021 Next-Generation Pharmacist® at the 12th annual awards program. All selected finalists will be featured in the September issue of 

For more information on the Next-Generation Pharmacist® awards program or to register for the event, click 

Pharmacy Times® and Parata Systems thank the following program sponsors: BD, CeraVe, National Healthcareer Association, Pharmacy Development Services, NCPA, and Americorp Financial LLC.

 ® is the industry-leading multimedia pharmacy network of community, health-system, oncology and specialty pharmacy platforms, providing practical clinical and professional information pharmacists can use in their everyday practices when counseling patients and interacting with other health care providers. Each issue and the website contain articles and features covering industry trends, medication errors, drug interactions, patient education, disease state management, patient counseling, product news, pharmacy law and more. Additionally, 

 is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Parata provides pharmacy technology solutions to reduce costs, improve health outcomes and enhance the patient experience by offering the most comprehensive pharmacy automation portfolio with medication adherence packaging, high-speed robotic dispensing technologies and pharmacy workflow solutions. Discover how Parata powers pharmacies to help people lead healthier lives at 

Ten category winners will be announced at the Next-Generation Pharmacist® of the Year gala, which will be held at 6pm on October 8, 2021.

Pharmacy Times and Parata Systems Announce the 2021 Next-Generation Pharmacist Finalists

Many community-based pharmacies brag about a familiarity with their patients and a focus on the patient’s short and long-term health. Norland Avenue Pharmacy in Chambersburg, Pennsylvania stands out for their staff-wide focus on practice transformation and patient care initiatives. Norland Avenue Pharmacy was recently recognized with the Flip the Pharmacy program’s Pharmacy of the Year Award.

The Flip the Pharmacy Pharmacy of the Year Award is given to a participating pharmacy that exhibits an exemplary commitment to transforming their practice model and to supporting the overall purpose of Flip the Pharmacy. Flip the Pharmacy is a five-year pharmacy transformation program aiming to re-work community-based pharmacy practice beyond filling prescriptions and toward an ongoing focus on a patient's health.

“Congratulations to Norland Avenue Pharmacy for being selected as this year’s Pharmacy of the Year,” announced Randy McDonough, PharmD, MS, BCGP, BCPS, FAPhA, Director of Practice Transformation for the Flip the Pharmacy program. “We had dozens of nominations, but the effort by the staff of Norland Avenue Pharmacy was significant and worthy our recognition.”

"We are so excited to win the first-ever Flip the Pharmacy Pharmacy of the Year Award! Our pharmacy staff has been working extremely hard to transform to a pharmacy that is truly focused on our patients and their health. This award recognizes that effort,” said Dr. Wayne

Myers, owner of Norland Avenue Pharmacy. “Deb Page was instrumental in getting our program started even as she was planning her retirement. She did an excellent job in transitioning the lead role to Ashli Yoder and Ashli has taken the reigns and run with them. Yet, our success is due to the entire staff getting onboard. We are extremely blessed by God to be honored with this award."

Using monthly change packages, Flip the Pharmacy coaches work with local pharmacy teams to implement the six key transformation domains.

Ashli pointed to Deb Page’s "can do" positive attitude and diligence in implementing the initial change packages as a key to the pharmacy’s success early in the program. Ashli said, “Deb has incredible vision and knew that Flip the Pharmacy would take us to a new next level in patient care. And she was right.”

Ongoing success has been achieved by building on the early foundation established by Deb and Ashli. 

“Over this past year, we have continued to build upon the foundations from the first year in the Flip the Pharmacy program. We have worked hard on the change packages each month and on submitting more eCare Plans with every new service we provided,” added Ashli. “We also have involved more of our pharmacy staff which has been incredible. We are able to brainstorm and bounce ideas off of each other to get the most out of each month's goal.”

Ashli said that her Flip the Pharmacy coaches have also been vitally important. “Our coaches, Margie and Ashley, have also been instrumental to our success. They have been a great resource to answer our questions, alert us of new opportunities, and keep us on track with our monthly meetings.”

The Flip the Pharmacy program hopes to directly support 1,000 pharmacies with direct coaching and implementation support and impact thousands more. To date, over 800 pharmacies and over 40 different Flip the Pharmacy teams are participating in the initiative.

Ashli firmly believes that the Flip the Pharmacy program has changed the way the Norland Avenue Pharmacy practices and provides patient care. 

“We were able to shift our mindset from a product-centered approach to a more patient-centered approach,” shared Ashli. “Over the past year and a half, we have taken blood pressure readings, given many vaccinations, grown our medication synchronization program, completed MTMs, and implemented an opioid safety pledge program – all of which we would not have been able to do without Flip the Pharmacy. We are extremely grateful for this program and everything it has done to help our pharmacy and help our patients.”

 and access the publicly available change packages.

The Flip the Pharmacy Pharmacy of the Year Award is given to a participating pharmacy that exhibits an exemplary commitment to transforming their practice model and to supporting the overall purpose of Flip the Pharmacy.

Press Releases